Novartis using Albumedix's platform to evaluate first-in-class therapeutics

Novartis and Albumedix have entered into an agreement to evaluate the development of several first-in-class therapeutics using Albumedix’s Veltis technology platform and associated technologies.
Novartis will evaluate molecules in combination with Albumedix´s engineered albumin variants for enhanced delivery. Beyond the modulation of pharmacokinetic profiles, the potential for novel routes of administration and mechanisms of action will be assessed. Novartis will evaluate Albumedix’s Veltis technology across multiple therapeutic areas and against multiple targets.
“This collaboration is an excellent example of how our Veltis technology platform holds great potential for optimizing the therapeutic performance of pharmaceuticals across a broad range of targets and indications” commented Dr. Phil Morton, chief technology officer, Albumedix. “We look forward to a strong collaboration with the various research teams at Novartis for the advancement of albumin-enabled therapeutics.”